Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Laboratories (CLB) EBITDA (2022 - 2025)

Core Laboratories' EBITDA history spans 4 years, with the latest figure at -$27.4 million for Q4 2025.

  • For Q4 2025, EBITDA fell 254.63% year-over-year to -$27.4 million; the TTM value through Dec 2025 reached $23.9 million, down 67.22%, while the annual FY2025 figure was $23.9 million, 67.22% down from the prior year.
  • EBITDA reached -$27.4 million in Q4 2025 per CLB's latest filing, down from $24.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $24.5 million in Q3 2025 to a low of -$27.4 million in Q4 2025.
  • Average EBITDA over 4 years is $14.7 million, with a median of $18.5 million recorded in 2023.
  • Peak YoY movement for EBITDA: soared 43.38% in 2023, then tumbled 254.63% in 2025.
  • A 4-year view of EBITDA shows it stood at $19.5 million in 2022, then decreased by 6.12% to $18.3 million in 2023, then fell by 3.34% to $17.7 million in 2024, then crashed by 254.63% to -$27.4 million in 2025.
  • Per Business Quant, the three most recent readings for CLB's EBITDA are -$27.4 million (Q4 2025), $24.5 million (Q3 2025), and $18.9 million (Q2 2025).